You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
金陵藥業(000919.SZ)半年度淨利潤預增171%-249%
格隆匯 07-12 17:31

格隆匯7月12日丨金陵藥業(000919.SZ)公佈,預計2021年半年度歸屬於上市公司股東的淨利潤6600萬元-8500萬元,同比增長171%-249%;扣除非經常性損益的淨利潤7200萬元-9200萬元,同比增長39%-78%。業績變動原因如下:

12020年初新冠肺炎疫情爆發公司所屬醫療機構投入各醫療資源及醫護人員全力抗擊新冠肺炎疫正常醫療工作受到影響導致公司2020年度醫療服務業收入和利潤下降。隨着我國新冠疫情得到有效控制,2021上半年公司所屬醫療機構醫療業務疫情爆發前的正常水平恢復,利潤與上年同期相比有所增長;時,公司醫藥工業板塊主要產品銷售收入較上年同期也有所增長,帶來利潤較上年同期同向上升

2報吿期內公司預計非經常性損益對歸屬於上市公司股東的淨利潤的影響額約-700萬元(上年同期影響額為-2743.96萬元),主要原因是公司持有的江蘇紫金農村商業銀行股份有限公司(紫金銀行)股票公允價值變動收益變動所致。截止2021630,公司上半年確認公允價值變動收益-2047.19萬元,由此減少歸屬於上市公司股東的淨利潤1740.11萬元。相較於上年同期因持有紫金銀行確認公允價值變動收益減少歸屬於上市公司股東的淨利4170.27萬元,有所減少。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account